Adagene将每份ADS定价为3.75美元，发行7000万美元

2026-04-02 19:35

Adagene (ADAG) stock slumped ~14% on Thursday during pre-market as it priced an underwritten public offering of ADS, aiming to raise approximately $70M in gross proceeds.
The company is offering ~18.67M ADSs at a price of $3.75 per ADS, which reflects its 30-day volume-weighted average price. Each ADS represents 1.25 ordinary shares.
The offering is expected to close on April 6, 2026.
Adagene, a clinical‑stage biopharmaceutical company based in Suzhou, China, is using the proceeds to fund its antibody‑based cancer immunotherapy pipeline, including ongoing clinical development and regulatory activities.
The offering featured participation from new and existing investors including Janus Henderson Investors, Deerfield Management, Invus, Sirenia and Columbia Threadneedle Investments, among others.
More on Adagene ADR
- Seeking Alpha’s Quant Rating on Adagene ADR
- Historical earnings data for Adagene ADR
- Financial information for Adagene ADR

More on Adagene ADR